Nuvalent
Cambridge
About Nuvalent
Nuvalent is a biotechnology company that develops targeted therapies for clinically proven kinase targets in cancer. Leveraging deep expertise in structure-based design, Nuvalent develops innovative small molecules with exquisite target selectivity to overcome resistance, minimize adverse events, and drive more durable responses. It is advancing a robust pipeline with parallel lead programs in ROS1-positive and ALK-positive NSCLC, along with multiple discovery-stage research programs.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 101 – 250
- Total funding: $1.8B
- Funding stage: IPO
- Last round: Post-IPO Secondary (Nov 2025)
- Ticker: nasdaq:NUVL
- Website: nuvalent.com
- Phone: +1 857 357 7000
Industries & Categories
Biotechnology, Life Science, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/nuvalent-16861 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.